Environmental and Facilities Services

SEP released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 231.61 M, actual EPS CNY 0.34

SEP to Release FY2025 Earnings on April 29 Pre-Market (BJT), Forecast Revenue CNY 1.284 B, EPS CNY 2.1

SEP to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Zijin Mining Profits from Investment in Saiens as Saiens' Stock Soars

SEP released FY2025 Q4 earnings on February 26 Pre-Market (BJT), actual revenue CNY 553.18 M, actual EPS CNY 0.3284

SEP released FY2025 annual earnings on February 26 Pre-Market (BJT), actual revenue CNY 1.251 B (forecast CNY 1.284 B), actual EPS CNY 1.15 (forecast CNY 2.1)

SEP released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 677.22 M, actual EPS CNY 0.7807

SEP released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 254.26 M, actual EPS CNY 0

SEP FY2025 Q3 Earnings Release Scheduled for October 30 After-Market BJT

SEP released FY2025 Semi-Annual earnings on August 20 During-Market (BJT), actual revenue CNY 422.97 M, actual EPS CNY 0.5143

SEP released FY2025 Q2 earnings on August 20 During-Market (BJT), actual revenue CNY 252.67 M, actual EPS CNY 0.3283

SEP FY2025 Semi-Annual Earning Release on August 21, 2025 (BJT)

Caisen stock rises, research report gives 'buy' rating

Eastwu Securities Issues Buy Rating on Sainse

Saince Reports 63.46% Revenue Growth but 77.68% Drop in Net Profit in Q1 2025

SEP released FY2025 Q1 earnings on April 24 During-Market (BJT), actual revenue CNY 170.3 M, actual EPS CNY 0.19

SEP to Release FY2025 Q1 Earnings on April 25 During-Market BJT

SEP to release FY2024 annual earnings on April 25, 2025 (BJT), forecast revenue CNY 1.122 B, EPS CNY 2.0466

Gao Weirong increases shareholding in Sains by 697,900 shares, totaling 20.1061 million RMB

SEP released FY2024 annual earnings on February 25 (BJT), actual revenue CNY 927.19 M (forecast CNY 1.122 B), actual EPS CNY 1.9 (forecast CNY 2.0466)

688480

SEP Environmental Co., Ltd. won the bid for the procurement project of Hezhang Dingshengxin Mining Development Co., Ltd., with an amount of 3.7996 million yuan. The operating revenue for 2024 is 927 million yuan, with a growth rate of 14.69%, and the net profit is 181 million yuan, with a growth rate of 100.11%. In the first half of 2025, the operating revenue is 423 million yuan, with a growth rate of 18.81%, and the net profit is 49 million yuan, a decrease of 57.50%

同壁财经

SEP (688480): Won the procurement project of Hezhang Dingshengxin Mining Development Co., Ltd., with a bid amount of 3.7996 million yuan

ARKG

159837

159849

510660

IBBQ

516820

LABU

688108

512290

516500

588860

Sanofi's investigational therapy Lunsekimig has shown promise in treating chronic respiratory diseases, meeting primary and key secondary endpoints in two Phase 2 studies. The AIRCULES study demonstrated significant reductions in asthma exacerbations and improved lung function in adults with moderate-to-severe asthma. The DUET study showed improvements in nasal congestion and polyp scores in patients with chronic rhinosinusitis with nasal polyps. Lunsekimig targets two inflammatory drivers, TSLP and IL-13, and was well tolerated. Sanofi plans further studies and will present detailed results at upcoming medical congresses.

nasdaq

Ark Genomic Revolution ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

iShares US Pharma

ChinaAMC SSE Health Care ETF Initiating Fund

Invesco Biotechnology & Genome ETF

VG Health

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Minsheng Royal CSI Biotechnology Theme ETF

Sanofi

Ping An CSI Medicine and Medical Device Innovation ETF

Direxion S&P Biotech Bull 3X

SINOMED

Health Care Select Sector SPDR

Guotai CSI Bio-medicine ETF

iShares Biotechnology ETF

SPDR S&P Biotech

ChinaAMC CSI Biotechnology Theme ETF

iShares Global Healthcare

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Direxion S&P Biotech Bear 3X

ChinaAMC SSE STAR Biology and Medicine ETF

Banco Santander SA-Spon

Proshares Ultra Nasdaq Biotech

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Sanofi's Lunsekimig Shows Promise In Respiratory Diseases

159892

513060

159316

159992

588250

159506

Sanofi's Sarclisa subcutaneous injector for multiple myeloma received a positive recommendation from the EMA CHMP, with EU decision pending and FDA review ongoing. Dupixent was approved in Japan for adults with moderate-to-severe bullous pemphigoid, showing promising trial results. However, Sanofi's late-stage IL-33 COPD trial failed to meet its primary endpoints, contrasting with positive data from competitors.

TradingView

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Key facts: Dupixent Japan approval; Sarclisa CHMP nod; IL‑33 COPD fails

02269

Earendil Labs, an AI-driven biotechnology company, has raised $787 million in financing to enhance its biologics discovery and development. The funding, supported by global investors including Sanofi and Dimension Capital, will accelerate the company's AI-driven R&D platform and expand its pipeline of antibody programs. The CEO emphasized AI's role in advancing therapeutic programs, with plans for multiple clinical developments. The investment aims to translate AI innovation into transformative medicines for patients with serious diseases, while strengthening strategic partnerships to enhance research and development efforts globally.

prnewswire

WUXI BIO

Eledon Pharmaceuticals

WuXi Biologics

07:30 ETEarendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development

Biotechnology startup Earendil Labs plans to go public in Hong Kong, aiming to raise up to $500 million (approximately HKD 3.9 billion). The company has partnerships with well-known pharmaceutical companies such as Sanofi and WuXi Biologics. Meanwhile, integrated circuit design company Guomin Technology and network solutions provider Feisuke Innovation have also begun their initial public offerings, planning to raise HKD 1.03 billion and HKD 1.66 billion, respectively, with strong oversubscription performance on their first day

Stheadline

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

WUXI APPTEC

WuXi AppTec

Biotech startup Earendil Labs is reported to raise HKD 3.9 billion through a Hong Kong IPO for AI drug development, collaborating with Sanofi and WuXi AppTec

A recent study suggests that the shingles vaccine may reduce the risk of developing Alzheimer's by 20%. Researchers have identified eight existing drugs, including Viagra and riluzole, that could potentially help fight dementia. The findings, published in Alzheimer's Research & Therapy, highlight the urgent need for further investigation into these drugs as dementia rates rise globally. The study emphasizes the importance of the shingles vaccine, which has shown significant protective effects against dementia in a large population study in Wales.

- A recent study suggests that the shingles vaccine may reduce the risk of developing Alzheimer's by up to 20%, based on data from hundreds of thousands of individuals.  
- Researchers are advocating for further investigation of existing drugs, including both the shingles vaccine and Viagra, for their potential benefits in combating dementia.  
- The analysis highlights the shingles vaccine's strong evidence as a preventive measure against dementia, with the new Shingrix vaccine possibly offering even greater protective effects.

Dow Jones

Viatris

Direxion Daily Biotech Top 5 Bull 2X ETF

Dynavax Tech

Pfizer

Teva Pharmaceutical Industries

These 8 drugs could help fight dementia - and they're already on the market

China's biotech outlicensing deals have surged to over US$52 billion in the first two months of 2026, driven by significant agreements such as Sino Biopharmaceutical's US$1.53 billion deal with Sanofi and Antengene's US$1.18 billion deal with UCB. This trend reflects a shift towards long-term partnerships as multinational companies seek innovative drug candidates from China. Analysts predict a continued increase in deal value, with expectations of a 50-60% rise in 2026, as global pharmaceutical firms intensify their search for new drug assets in China.

SCMP

SBP GROUP

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

China biotech outlicensing tops US$52 billion in first 2 months

SEP(688480.SH)